Cassava Sciences Executive Chairman outlines Phase 3 trial timelines and transparency pledge

FILANA THERAPEUTICS, INC.

First Phase 3 simufilam trial (804 patients) to read out by Dec 2024; second by June 2025.
Rick Barry takes roles of Executive Chairman and principal executive officer until new CEO.
Company commits to rigorous science and timely disclosure of material news, good or bad.
Trial data held by Premier Research; biostatistics by Pentara – Cassava won't see results early.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.